Drug Trial Radar · NCT07188766
Efficacy of Liberal Versus Restricted IV Fluid Approach in the Management of Sickle Cell Vaso-Occlusive Crisis
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
394
Planned (sponsor's estimate)
Start
Oct 5, 2025
Primary completion
Aug 2028
Study completion Oct 2028
Sponsor
- Lead sponsor
- Imam Abdulrahman Bin Faisal UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 23, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Sickle cell disease (SCD) is a prevalent inherited blood disorder characterized by vaso-occlusive crises (VOCs), which lead to severe pain and complications. Despite hydration being a cornerstone of VOC management, the optimal fluid strategy remains uncertain. This study evaluates restrictive versus liberal fluid management strategies in patients with acute VOC. This multi-center, open-label, non-inferiority RCT will enroll patients with SCD presenting with acute VOC. Participants will be randomized to either a restrictive or liberal intravenous fluid management protocol. Primary outcome is pain score reduction. Secondary outcomes include time to pain resolution, ED length of stay, hospital admission rate, cumulative opioid dose, adverse events (incidence of fluid overload, pulmonary congestion), acute chest syndrome, incidence of acute kidney injury, revisit rates within 72 hours of ED discharge, need for intensive care or high-dependency unit admission, need for additional interventions, and 28 days overall mortality. Data will be analyzed using intention-to-treat principles. We hypothesize that a restrictive fluid strategy will achieve non-inferior pain control compared to a liberal strategy, while minimizing fluid-related complications. This study will provide evidence to inform clinical guidelines for fluid management in SCD patients experiencing VOCs.
Conditions
- SCD
- Vaso Occlussive Crisis
Interventions
Sodium Chloride (NaCl) 0.9 %Drug
Keep vein open rate
Sodium Chloride (NaCl) 0.9 %Drug
IV bolus of 20 mL/kg of normal saline over 1 hour, followed by maintenance fluids at 1.5-2 ml/kg times the calculated daily maintenance requirements
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Pain intensityTime frame: Baseline (within 30 minutes post admission), 1 hour, then hourly until ED discharge or 24- 48- and 72-hours post-admission ( for admitted patients)
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
John Hopkins Aramco Healthcare
Dhahran, Saudi Arabia · Recruiting
King Fahad Military Medical Complex
Dhahran, Saudi Arabia · Recruiting
Jubail General Hospital
Jubail, Saudi Arabia · Recruiting
King Saud University Medical City
Riyadh, Saudi Arabia · Recruiting
King Fahd Hospital of the University
Dammam, Eastern Province, Saudi Arabia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.